Drug Search Results
More Filters [+]

Aldesleukin

Alternative Names: aldesleukin, proleukin, recombinant human interleukin-2, ril-2, ilt-101, ilt101
Latest Update: 2024-10-05
Latest Update Note: Clinical Trial Update

Product Description

Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Chiron
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aldesleukin

Countries in Clinic: France, Hong Kong, Israel, Korea, New Zealand, United States

Active Clinical Trial Count: 16

Highest Development Phases

Phase 2: Acute Myeloid Leukemia|Adenocarcinoma|Alzheimer Disease|Bipolar Disorder|Bladder Cancer|COVID-19|Carcinoma, Adenosquamous|Cholangiocarcinoma|Chronic Myeloid Leukemia|Colorectal Cancer|Conjunctivitis, Allergic|Digestive System Cancer|Endometrial Cancer|Esophageal Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Kidney Cancer|Melanoma|Neuroblastoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Rhinitis, Allergic, Seasonal|Soft Tissue Cancer|Squamous Cell Carcinoma|Synovial Sarcoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Type 1 Diabetes

Phase 1: Breast Cancer|Cervical Cancer|Hepatitis B|Lung Cancer|Oncology Solid Tumor Unspecified|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

0752-20-HMO

P2

Recruiting

Soft Tissue Cancer|Transitional Cell Carcinoma|Bladder Cancer|Melanoma|Ovarian Cancer|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Neuroblastoma|Synovial Sarcoma

2027-12-30

Pro2022002198

P1

Recruiting

Lung Cancer|Gastrointestinal Cancer|Breast Cancer|Uterine Cancer|Cervical Cancer

2026-09-01

Study of LN 145 in patients with Metastatic Non-Small-Cell Lung Cancer

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2026-05-05

IL-2-AD

P2

Recruiting

Alzheimer Disease

2025-09-01

Recent News Events